Stockreport

Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' [Seeking Alpha]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF REC-4881's efficacy in FAP is unremarkable versus Celebrex, with uncertain regulatory and adoption prospects. RXRX's oncology pipeline, including REC-617 and REC-3565 [Read more]